Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide

Glioblastomas (GBM) are the most common and aggressive form of primary malignant brain tumor in the adult population, and, despite modern therapies, patients often develop recurrent disease, and the disease remains incurable with median survival below 2 years. Resistance to bevacizumab is driven by...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodi, Alessia, Pandey, Renu, Chiou, Jennifer, Bhattacharya, Ayon, Huang, Shiliang, Pan, Xingxin, Burgman, Brandon, Yi, S. Stephen, Tiziani, Stefano, Brenner, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549210/
https://www.ncbi.nlm.nih.gov/pubmed/36226069
http://dx.doi.org/10.3389/fonc.2022.900082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549210/
https://www.ncbi.nlm.nih.gov/pubmed/36226069
http://dx.doi.org/10.3389/fonc.2022.900082

Ejemplares similares